SOTYKTU Clinical, Regulatory and Commercial Intelligence Report 2026

Bristol Myers Squibb's SOTYKTU (deucravacitinib), a first-in-class TYK2 inhibitor, has received FDA approval for psoriatic arthritis in March 2026, expanding its commercial potential beyond plaque psoriasis. The drug demonstrates sustained efficacy with PASI 75 response rates of 67%-73% through five years and over 5,000 patient-years of safety data. Market analysis forecasts SOTYKTU sales across seven major markets through 2034, with growth driven by oral convenience, selective mechanism of action, and potential expansion into additional immune-mediated inflammatory disease indications including lupus, Sjogren's syndrome, and Crohn's disease.